{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:40:10Z","timestamp":1791463210573,"version":"4.3.4"},"reference-count":29,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The hallmark of haemophilia A (HA) therapy is prophylaxis, aimed at spontaneous bleeding prevention. Emicizumab provides a viable alternative to intravenous factor replacement therapy. However, data on its use in infants are limited. This single\u2010centre open arm prospective study reports on emicizumab prophylaxis in infants. We included severe HA patients under 1\u2009year who started emicizumab prophylaxis since 2018, with longitudinal follow\u2010up. The study collected data on demographics, clinical and laboratory variables, the occurrence of bleeding events, surgeries and treatment outcomes. Of the 27 enrolled infants, whose median age at prophylaxis initiation was 7\u2009months, 24 primarily choose to start emicizumab therapy (3\/27 switched from FVIII prophylaxis due to development of FVIII inhibitors). The median age for prophylaxis initiation decreased to 3\u2009months in 2023. Following emicizumab initiation, the median calculated ABR decreased, and no intracranial haemorrhages were observed. Thrombin generation showed a significant improvement in peak height and endogenous thrombin potential at steady state after a loading period. Our study highlights a shift towards early prophylaxis in the era of non\u2010replacement therapies. It underscores the need for continuous evaluation and refinement of treatment approaches, emphasizing personalized care and diligent monitoring in the evolving field of paediatric haemophilia care.<\/jats:p>","DOI":"10.1111\/bjh.19312","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T23:20:05Z","timestamp":1706138405000},"page":"1375-1382","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Emicizumab prophylaxis in infants: Single\u2010centre experience"],"prefix":"10.1111","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3971-0336","authenticated-orcid":false,"given":"Sarina","family":"Levy\u2010Mendelovich","sequence":"first","affiliation":[{"name":"National Haemophilia Center and Thrombosis &amp; Hemostasis Institute Sheba Medical Center  Ramat Gan Israel"},{"name":"Faculty of Medicine Amalia Biron Research Institute of Thrombosis &amp; Hemostasis, Tel Aviv University  Tel Aviv Israel"},{"name":"Talpiot Medical Leadership Program Sheba Medical center  Ramat Gan Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Greenberg\u2010kushnir","sequence":"additional","affiliation":[{"name":"Department of Paediatric Hematology\u2010Oncology The Edmond and Lily Safra Children's Hospital, Sheba Medical Center  Ramat Gan Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Budnik","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology\/Oncology University of Iowa  Iowa City Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8329-8409","authenticated-orcid":false,"given":"Assaf Arie","family":"Barg","sequence":"additional","affiliation":[{"name":"National Haemophilia Center and Thrombosis &amp; Hemostasis Institute Sheba Medical Center  Ramat Gan Israel"},{"name":"Faculty of Medicine Amalia Biron Research Institute of Thrombosis &amp; Hemostasis, Tel Aviv University  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omri","family":"Cohen","sequence":"additional","affiliation":[{"name":"National Haemophilia Center and Thrombosis &amp; Hemostasis Institute Sheba Medical Center  Ramat Gan Israel"},{"name":"Faculty of Medicine Amalia Biron Research Institute of Thrombosis &amp; Hemostasis, Tel Aviv University  Tel Aviv Israel"},{"name":"Department of Medicine and Surgery University of Insubria  Varese Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einat","family":"Avishai","sequence":"additional","affiliation":[{"name":"National Haemophilia Center and Thrombosis &amp; Hemostasis Institute Sheba Medical Center  Ramat Gan Israel"},{"name":"Faculty of Medicine Amalia Biron Research Institute of Thrombosis &amp; Hemostasis, Tel Aviv University  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tami","family":"Barazani\u2010Brutman","sequence":"additional","affiliation":[{"name":"National Haemophilia Center and Thrombosis &amp; Hemostasis Institute Sheba Medical Center  Ramat Gan Israel"},{"name":"Faculty of Medicine Amalia Biron Research Institute of Thrombosis &amp; Hemostasis, Tel Aviv University  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tami","family":"Livnat","sequence":"additional","affiliation":[{"name":"National Haemophilia Center and Thrombosis &amp; Hemostasis Institute Sheba Medical Center  Ramat Gan Israel"},{"name":"Faculty of Medicine Amalia Biron Research Institute of Thrombosis &amp; Hemostasis, Tel Aviv University  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3494-9823","authenticated-orcid":false,"given":"Gili","family":"Kenet","sequence":"additional","affiliation":[{"name":"National Haemophilia Center and Thrombosis &amp; Hemostasis Institute Sheba Medical Center  Ramat Gan Israel"},{"name":"Faculty of Medicine Amalia Biron Research Institute of Thrombosis &amp; Hemostasis, Tel Aviv University  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201002\u2010683169"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13998"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20100040\u20101717114"},{"issue":"1","key":"e_1_2_12_5_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102306","article-title":"Pharmacokinetics and coagulation biomarkers in persons with hemophilia A (PwHA) and FVIII inhibitors receiving Emicizumab in the phase IIIb STASEY study [abstract]","volume":"4","author":"Kiialainen A","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201008\u2010801662"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538\u20107836.2011.04214.x"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511769"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001869"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803550"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(19)30054\u20107"},{"key":"e_1_2_12_14_1","unstructured":"U.S. Food and Drug Administration [Internet].FDA approves Emicizumab\u2010kxwh for hemophilia a with or without factor VIII inhibitors. [cited 2018 Oct]. Available from:www.fdagov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm622564htm."},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13848"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27886"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28942"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14353"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20100039\u20101688687"},{"key":"e_1_2_12_20_1","unstructured":"CalhoonW McInerneyM CalatzisA ChenD AdamkewiczJ MorrisM.Evaluation of a dedicated calibrator and controls for emicizumab quantification. Paper presented at: 4th Scientific Meeting of the Thrombosis and Hemostasis Societies of North America (THSNA); April 22\u201325 2018; Chicago IL. Abstract."},{"issue":"5","key":"e_1_2_12_21_1","first-page":"553","article-title":"Thrombin generation, a function test of the haemostatic\u2010thrombotic system","volume":"96","author":"Hemker HC","year":"2006","journal-title":"Thromb Haemost"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.102178"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.209619"},{"key":"e_1_2_12_24_1","unstructured":"PipeSW CollinsP DhalluinC KenetG SchmittC BuriM et\u00a0al.Emicizumab prophylaxis for the treatment of infants with severe hemophilia A without factor VIII inhibitors: results from the interim analysis of the HAVEN 7 study. Abstract #187. Presented at the 2022 American Society of Hematology Annual Meeting and Exposition; December 10 2022; New Orleans Louisiana."},{"key":"e_1_2_12_25_1","doi-asserted-by":"crossref","unstructured":"KiialainenA PipeS FijnvandraatK KenetG SchmittC BuriM et\u00a0al.Pharmacodynamic Biomarkers in Infants with Hemophilia A Receiving Emicizumab in HAVEN 7. Abstract #1238. Presented at the 2023 American Society of Hematology Annual Meeting and Exposition; December 9 2023; San Diego.","DOI":"10.1182\/blood-2023-173015"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16964"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102014\u201010\u2010551952"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15342"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100278"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13888"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.19312","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T15:37:24Z","timestamp":1712763444000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.19312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1111\/bjh.19312"],"URL":"https:\/\/doi.org\/10.1111\/bjh.19312","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,24]]},"assertion":[{"value":"2023-12-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}